🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “ALX ONCOLOGY HOLDINGS INC” Clear

  1. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  2. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

  3. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  5. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  6. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Zanidatamab

    ALX ONCOLOGY HOLDINGS INC

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial

  8. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  9. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  10. Evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Bladder Cancer

    phase 1 small molecule completed

    1 trial

  11. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  12. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Higher Risk Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  13. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources